Cargando…
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
Glioblastoma (GBM) is the most prevalent primary central nervous system tumour in adults. The lethality of GBM lies in its highly invasive, infiltrative, and neurologically destructive nature resulting in treatment failure, tumour recurrence and death. Even with current standard of care treatment wi...
Autores principales: | Jones, Dylan, Whitehead, Clarissa A., Dinevska, Marija, Widodo, Samuel S., Furst, Liam M., Morokoff, Andrew P., Kaye, Andrew H., Drummond, Katharine J., Mantamadiotis, Theo, Stylli, Stanley S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164021/ https://www.ncbi.nlm.nih.gov/pubmed/36302993 http://dx.doi.org/10.1007/s11010-022-04584-0 |
Ejemplares similares
-
Inhibition of Radiation and Temozolomide-Induced Glioblastoma Invadopodia Activity Using Ion Channel Drugs
por: Dinevska, Marija, et al.
Publicado: (2020) -
Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs
por: Whitehead, Clarissa A., et al.
Publicado: (2018) -
Small extracellular vesicles promote invadopodia activity in glioblastoma cells in a therapy-dependent manner
por: Whitehead, Clarissa A., et al.
Publicado: (2023) -
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
por: Bibby, Becky A. S., et al.
Publicado: (2021) -
Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)